NO20083813L - Nitrogenholdig heterocyklisk derivat, og farmasoytisk middel omfattende derivatet som aktiv bestanddel - Google Patents

Nitrogenholdig heterocyklisk derivat, og farmasoytisk middel omfattende derivatet som aktiv bestanddel

Info

Publication number
NO20083813L
NO20083813L NO20083813A NO20083813A NO20083813L NO 20083813 L NO20083813 L NO 20083813L NO 20083813 A NO20083813 A NO 20083813A NO 20083813 A NO20083813 A NO 20083813A NO 20083813 L NO20083813 L NO 20083813L
Authority
NO
Norway
Prior art keywords
disease
derivative
compound
salt
oxide
Prior art date
Application number
NO20083813A
Other languages
English (en)
Norwegian (no)
Inventor
Shinya Kusuda
Toshihiko Nishiyama
Kazuya Hashimua
Junya Ueda
Shiro Shibayama
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of NO20083813L publication Critical patent/NO20083813L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
NO20083813A 2006-03-10 2008-09-08 Nitrogenholdig heterocyklisk derivat, og farmasoytisk middel omfattende derivatet som aktiv bestanddel NO20083813L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006066451 2006-03-10
PCT/JP2007/054684 WO2007105637A1 (ja) 2006-03-10 2007-03-09 含窒素複素環誘導体およびそれらを有効成分とする薬剤

Publications (1)

Publication Number Publication Date
NO20083813L true NO20083813L (no) 2008-12-10

Family

ID=38509460

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083813A NO20083813L (no) 2006-03-10 2008-09-08 Nitrogenholdig heterocyklisk derivat, og farmasoytisk middel omfattende derivatet som aktiv bestanddel

Country Status (15)

Country Link
US (1) US8003642B2 (ja)
EP (1) EP1995246A4 (ja)
JP (1) JPWO2007105637A1 (ja)
KR (1) KR20090008217A (ja)
CN (1) CN101443322A (ja)
AU (1) AU2007225836A1 (ja)
BR (1) BRPI0708731A2 (ja)
CA (1) CA2644368A1 (ja)
EA (1) EA200870344A1 (ja)
MA (1) MA30294B1 (ja)
MX (1) MX2008011414A (ja)
NO (1) NO20083813L (ja)
RU (1) RU2008140144A (ja)
WO (1) WO2007105637A1 (ja)
ZA (1) ZA200807767B (ja)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4736043B2 (ja) 2003-03-14 2011-07-27 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
TWI400232B (zh) * 2004-09-13 2013-07-01 Ono Pharmaceutical Co 含氮雜環衍生物及以該含氮雜環衍生物為有效成分之藥劑
NZ575514A (en) 2005-07-09 2009-11-27 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
LT2474545T (lt) 2005-12-13 2017-02-27 Incyte Holdings Corporation Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai
AU2007225836A1 (en) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
CL2007003061A1 (es) 2006-10-26 2008-08-01 Astrazeneca Ab Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2.
EP2120928A2 (en) * 2007-02-15 2009-11-25 Pfizer Limited Pharmaceutical compositions and methods for ccr5 antagonists
LT3070090T (lt) 2007-06-13 2019-06-25 Incyte Holdings Corporation Janus kinazės inhibitoriaus (r)-3-(4-(7h-pirol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropannitrilo druskų panaudojimas
ES2445199T3 (es) 2008-06-05 2014-02-28 Glaxo Group Limited Derivados de benzpirazol como inhibidores de PI3-quinasas
WO2009147190A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
US8536169B2 (en) 2008-06-05 2013-09-17 Glaxo Group Limited Compounds
EP2324028A2 (en) 2008-08-04 2011-05-25 AstraZeneca AB Therapeutic agents 414
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
GB0902434D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
GB0902406D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
ES2542551T3 (es) 2009-03-09 2015-08-06 Glaxo Group Limited 4-Oxadiazol-2-il-indazoles como inhibidores de PI3 cinasas
AR076220A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivados de pirazol [4,5 - e] pirimidina
AR076221A1 (es) * 2009-04-09 2011-05-26 Astrazeneca Ab Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
SI2899191T1 (sl) 2009-04-30 2017-11-30 Glaxo Group Limited Z oksazolom substituirani indazoli kot PI3-kinazni inhibitorji
MY161416A (en) 2009-05-22 2017-04-14 Incyte Holdings Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4yl)-1h-pyrazol-1-yl]octane-or heptane-nitrile as jak inhibitors
JP5775070B2 (ja) * 2009-05-22 2015-09-09 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体
US9249145B2 (en) * 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
AR081315A1 (es) * 2010-03-10 2012-08-08 Incyte Corp Derivados heterociclicos de piperidin y pirimidin -4-il-azetidina, una forma cristalina de la sal del acido acetonitriladipico de un derivado pirimidinico, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades relacionadas con la inhibicion de jak-1, t
ME02445B (me) 2010-05-21 2016-09-20 Incyte Holdings Corp Topikalna formulacija za inhibiciju jak-a
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
AR083933A1 (es) 2010-11-19 2013-04-10 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
DK2683643T3 (da) 2011-03-09 2019-08-12 Richard G Pestell Prostatacancercellelinjer, gensignaturer og anvendelser deraf
US8975235B2 (en) 2011-03-20 2015-03-10 Intermune, Inc. Lysophosphatidic acid receptor antagonists
PE20140832A1 (es) 2011-06-20 2014-07-14 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CA2873743C (en) 2012-05-14 2022-12-06 Prostagene, Llc Using modulators of ccr5 for treating cancer
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
CA3178452A1 (en) 2012-11-15 2014-05-22 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
LT3489239T (lt) 2013-03-06 2022-03-10 Incyte Holdings Corporation Jak inhibitoriaus gamybos būdai ir tarpiniai junginiai
JP6026024B2 (ja) 2013-06-27 2016-11-16 ファイザー・インク 複素芳香族化合物およびそのドーパミンｄ１リガンドとしての使用
MY195091A (en) 2013-08-07 2023-01-10 Incyte Corp Sustained Release Dosage Forms for a JAK1 Inhibitor
EA028819B1 (ru) 2013-10-25 2018-01-31 Новартис Аг Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
EP3200786B1 (en) 2014-10-03 2019-08-28 Novartis AG Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
ES2881228T3 (es) * 2015-02-16 2021-11-29 Univ Queensland Sulfonilureas y compuestos relacionados y uso de los mismos
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
WO2019152374A1 (en) 2018-01-30 2019-08-08 Incyte Corporation Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
MX2020010322A (es) 2018-03-30 2022-11-30 Incyte Corp Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
EP3936192A4 (en) 2019-03-06 2022-11-16 Daiichi Sankyo Company, Limited PYRROLOPYRAZOL DERIVATIVES
CN110590748A (zh) * 2019-10-03 2019-12-20 黄泳华 芳香基氨基苄基哌嗪氮氧化物及其组合物与用途
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1063744A (en) * 1964-05-25 1967-03-30 American Cyanamid Co 4-substituted-4'-tertiary aminoalkoxy biphenyls
US5169855A (en) * 1990-03-28 1992-12-08 Du Pont Merck Pharmaceutical Company Piperidine ether derivatives as psychotropic drugs or plant fungicides
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
IL118469A (en) 1995-06-15 2000-08-13 Tanabe Seiyaku Co Naphthalene derivatives their preparation and intermediates thereof
ES2217404T3 (es) 1996-03-28 2004-11-01 Glaxo Group Limited Derivados de pirrolopirrolona como inhibidores de la elastasa de neutrofilos.
WO1998025605A1 (en) 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
CA2275602C (en) 1996-12-19 2003-07-22 Hoechst Marion Roussel, Inc. Novel carboxy substituted cyclic carboxamide derivatives
ZA985542B (en) 1997-07-03 1999-04-07 Smithkline Beecham Corp Substituted benzanilides as CCR5 receptor ligands antiinflammatory agents and antiviral agents
WO1999004794A1 (en) 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
GB9716657D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
EP1020445B1 (en) 1997-10-02 2008-08-13 Eisai R&D Management Co., Ltd. Fused pyridine derivatives
AR013669A1 (es) 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
AU1504599A (en) 1997-12-17 1999-07-05 Shionogi & Co., Ltd. Novel pyridine compounds
WO1999032100A2 (en) 1997-12-19 1999-07-01 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative
JP2002501898A (ja) 1998-02-02 2002-01-22 メルク エンド カムパニー インコーポレーテッド ケモカイン受容体活性の環状アミン調節剤
GB9803226D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
CA2329777A1 (en) 1998-04-27 1999-11-04 Dashyant Dhanak Ccr-3 receptor antagonists
EP1073434A1 (en) 1998-04-27 2001-02-07 Smithkline Beecham Corporation Ccr-3 receptor antagonists
WO2000004003A1 (en) 1998-07-14 2000-01-27 Smithkline Beecham Corporation Ccr-3 receptor antagonists
BR9912406A (pt) 1998-07-28 2001-04-24 Smithkline Beecham Corp Compostos de anilida substituida e métodos
US6399656B1 (en) 1998-07-28 2002-06-04 Smithkline Beecham Corporation Compounds and methods
WO2000010965A2 (en) * 1998-08-20 2000-03-02 Takeda Chemical Industries, Ltd. Quaternary ammonium salts and their use as anti-hiv agents
WO2000010653A1 (en) 1998-08-24 2000-03-02 Orlimar Golf Equipment Company, Llc Iron golf club head and club
WO2000021916A1 (fr) 1998-10-15 2000-04-20 Takeda Chemical Industries, Ltd. Procede de preparation de derives d'amine
WO2000027800A1 (en) 1998-11-09 2000-05-18 Smithkline Beecham Corporation Ccr-3 receptor antagonists
WO2000027835A1 (en) 1998-11-09 2000-05-18 Smithkline Beecham Corporation Ccr-3 receptor antagonists
WO2000027843A1 (en) 1998-11-09 2000-05-18 Smithkline Beecham Corporation Ccr-3 receptor antagonists
CN1163484C (zh) 1998-11-17 2004-08-25 霍夫曼-拉罗奇有限公司 4-芳酰基-哌啶-ccr-3受体拮抗剂ⅲ
CA2350903A1 (en) 1998-11-20 2000-06-02 F. Hoffmann-La Roche Ag Pyrrolidine derivatives-ccr-3 receptor antagonists
TR200101397T2 (tr) 1998-11-20 2001-11-21 F.Hoffmann-La Roche Ag Piperidin CCR-3 reseptörü antagonistleri
WO2000034278A1 (fr) 1998-12-04 2000-06-15 Toray Industries, Inc. Derives triazolo, et inhibiteurs de chimiokines contenant ces derives comme ingredient actif
EP1156807A4 (en) 1998-12-18 2002-04-03 Du Pont Pharm Co N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS
EP1140087A4 (en) 1998-12-18 2002-04-03 Du Pont Pharm Co N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS
EP1140086A4 (en) 1998-12-18 2002-04-03 Du Pont Pharm Co N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS
CA2347912A1 (en) 1998-12-18 2000-06-22 Soo S. Ko Heterocyclic piperidines as modulators of chemokine receptor activity
KR20010101287A (ko) 1998-12-18 2001-11-14 블레어 큐. 퍼거슨 케모킨 수용체 활성의 조절자로서 ｎ-우레이도알킬-피페리딘
AU2056700A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity
DE69926919D1 (de) 1998-12-18 2005-09-29 Bristol Myers Squibb Pharma Co N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
CA2353635A1 (en) 1998-12-21 2000-06-29 Takeda Chemical Industries, Ltd. Anilide derivative, production and use thereof
EP1013276A1 (en) 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
US7217714B1 (en) 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
PE20001420A1 (es) 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
EP1140072B1 (en) 1998-12-30 2004-04-14 Smithkline Beecham Corporation Compounds and methods
MXPA01007033A (es) 1999-01-13 2003-07-21 Millennium Pharm Inc Heterociclos funcionalizados como moduladores de receptores de quimiocinas.
WO2000041685A1 (en) 1999-01-19 2000-07-20 Smithkline Beecham Corporation Ccr-3 receptor antagonists
AU3215500A (en) 1999-01-25 2000-08-07 Smithkline Beecham Corporation Compounds and methods
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902452D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902459D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902461D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
JP2000309598A (ja) 1999-02-25 2000-11-07 Takeda Chem Ind Ltd 多剤結合型新規化合物、その製造法および用途
US6489354B1 (en) 1999-03-02 2002-12-03 Merck & Co., Inc. 3-alkyl substituted pyrrolidine modulators of chemokine receptor activity
US6362201B1 (en) 1999-03-02 2002-03-26 Merck & Co., Inc. 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity
US6372764B1 (en) 1999-03-02 2002-04-16 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
WO2000051608A1 (en) 1999-03-02 2000-09-08 Merck & Co., Inc. 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
WO2000053172A1 (en) 1999-03-08 2000-09-14 Smithkline Beecham Corporation Ccr-3 receptor antagonists
AU3521400A (en) 1999-03-10 2000-09-28 Smithkline Beecham Corporation Compounds and methods
AU2942000A (en) 1999-03-11 2000-09-28 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivatives
NZ514709A (en) 1999-03-24 2003-03-28 Anormed Inc Heterocyclic substituted 1,4-benzene dimethanamine derivatives useful for treating disorders mediated by chemokine receptor binding or associated with an abnormal immune response
CN1344266A (zh) 1999-03-26 2002-04-10 阿斯特拉曾尼卡有限公司 新的化合物
US6498161B1 (en) 1999-04-06 2002-12-24 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
US6265434B1 (en) 1999-04-06 2001-07-24 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
US6399619B1 (en) 1999-04-06 2002-06-04 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
US6248755B1 (en) 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
US6358697B2 (en) 1999-04-21 2002-03-19 Children's Hospital Medical Center Intracellular pharmaceutical targeting
AU4143300A (en) 1999-04-28 2000-11-17 Takeda Chemical Industries Ltd. Cyclic amide compounds, process for the preparation of the same and uses thereof
JP2002543126A (ja) 1999-05-03 2002-12-17 スミスクライン・ビーチャム・コーポレイション Ｃｘｃｒ−４受容体アンタゴニスト−トロンボポエチン模倣物
US6391865B1 (en) 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
MXPA01011116A (es) 1999-05-04 2002-06-04 Schering Corp Terapia de hiv de combinacion de antagonista ccr5 - interferon alfa pegilado.
RU2299206C9 (ru) 1999-05-04 2007-11-20 Шеринг Корпорейшн Производные пиперазина, фармацевтические композиции, их содержащие, и применение в качестве антагонистов ccr5
ES2246233T3 (es) 1999-05-04 2006-02-16 Schering Corporation Derivados de piperidina utiles como antagonistas de ccr5.
CA2373073A1 (en) 1999-05-07 2000-11-16 Takeda Chemical Industries, Ltd. Cyclic compounds and uses thereof
WO2000069815A1 (en) 1999-05-13 2000-11-23 Teijin Limited Ureido-substituted cyclic amine derivatives and their use as drug
ES2250132T3 (es) 1999-05-18 2006-04-16 Teijin Limited Remedios preventivos para enfermedades asociadas a quimioquinas.
EP1181310A1 (en) 1999-05-27 2002-02-27 Celltek Biotechnologies Inc. Chemokine receptor ccr3 antagonists
US6165261A (en) 1999-06-10 2000-12-26 Ergon, Inc. Water-resistant gypsum composition
DE60027011T2 (de) 1999-07-28 2006-12-07 Kirin Beer K.K. Harnstoffderivate als CCR-3 Rezeptor-Inhibitoren
SE9902987D0 (sv) * 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
JP4831906B2 (ja) 1999-08-27 2011-12-07 ケモセントリックス， インコーポレイテッド Ｃｘｃｒ３機能を調節するための複素環式化合物および方法
WO2001040227A1 (fr) 1999-12-03 2001-06-07 Ono Pharmaceutical Co., Ltd. Derives triazaspiro[5.5]undecane et medicaments contenant ces derives en tant que principe actif
GB0011838D0 (en) 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
US6894063B2 (en) * 2000-09-14 2005-05-17 Schering Corporation Substituted urea neuropeptide Y Y5 Receptor antagonists
CA2422013A1 (en) * 2000-09-14 2002-03-21 Schering Corporation Substituted urea neuropeptide y y5 receptor antagonists
AR031130A1 (es) 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
IL156304A0 (en) 2000-12-11 2004-01-04 Tularik Inc Cxcr3 antagonists
GB0100102D0 (en) 2001-01-03 2001-02-14 Syngenta Participations Ag Organic compounds
WO2002074758A2 (en) 2001-03-16 2002-09-26 Abbott Laboratories Novel amines as histamine-3 receptor ligands and their therapeutic applications
MXPA03008529A (es) 2001-03-19 2004-06-30 Ono Pharmaceutical Co Derivado de triazaspiro [5.5]undecano y composicion farmaceutica que comprende el mismo como ingrediente activo.
GB0108099D0 (en) 2001-03-30 2001-05-23 Hoffmann La Roche Aminopiperidine derivatives
EP1381592A1 (en) * 2001-04-13 2004-01-21 Boehringer Ingelheim Pharmaceuticals Inc. 1,4-disubstituted benzo-fused compounds
US6495569B1 (en) 2001-04-19 2002-12-17 Millennium Pharmaceuticals, Inc. Imidazolidine compounds
US6469002B1 (en) 2001-04-19 2002-10-22 Millennium Pharmaceuticals, Inc. Imidazolidine compounds
US6720321B2 (en) * 2001-06-05 2004-04-13 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzo-fused cycloalkyl urea compounds
JP3829136B2 (ja) 2001-06-20 2006-10-04 ファイザー・プロダクツ・インク 新規なスルホン酸誘導体
US6867221B2 (en) 2001-08-30 2005-03-15 Kowa Co., Ltd. Cyclic amine compounds and pharmaceutical composition containing the same
US20050143372A1 (en) 2001-10-30 2005-06-30 Shomir Ghosh Compounds, pharmaceutical compositions and methods of use therefor
NZ532291A (en) * 2001-11-14 2005-11-25 Schering Corp Cannabinoid receptor ligands
TW200302717A (en) 2002-02-06 2003-08-16 Schering Corp Novel gamma secretase inhibitors
US20030195192A1 (en) * 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
EP1554253A4 (en) 2002-06-03 2006-09-20 Smithkline Beecham Corp IMIDAZOLIUM COMPOUNDS INHIBITORS OF CXCR3
EP1552842A1 (en) 2002-06-07 2005-07-13 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives
JPWO2004026873A1 (ja) 2002-09-18 2006-01-19 小野薬品工業株式会社 トリアザスピロ［５．５］ウンデカン誘導体およびそれらを有効成分とする薬剤
US7247725B2 (en) * 2002-10-30 2007-07-24 Merck & Co., Inc. Gamma-aminoamide modulators of chemokine receptor activity
ATE552253T1 (de) 2002-11-08 2012-04-15 Novartis Int Pharm Ltd 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren
WO2004046110A1 (ja) 2002-11-15 2004-06-03 Yamanouchi Pharmaceutical Co., Ltd. メラニン凝集ホルモン受容体拮抗剤
WO2004052862A1 (ja) * 2002-12-10 2004-06-24 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
JP2004256531A (ja) 2003-02-07 2004-09-16 Takeda Chem Ind Ltd 三環性化合物、その製造法および用途
GB0305426D0 (en) * 2003-03-08 2003-04-16 Glaxo Group Ltd Novel compounds
JP4736043B2 (ja) 2003-03-14 2011-07-27 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
AU2004233828B2 (en) 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
WO2005023771A1 (ja) * 2003-09-05 2005-03-17 Ono Pharmaceutical Co., Ltd. ケモカインレセプターアンタゴニストおよびその医薬用途
TWI400232B (zh) 2004-09-13 2013-07-01 Ono Pharmaceutical Co 含氮雜環衍生物及以該含氮雜環衍生物為有效成分之藥劑
JP2007063268A (ja) 2005-08-05 2007-03-15 Tanabe Seiyaku Co Ltd 医薬組成物
CA2619881A1 (en) 2005-08-16 2007-02-22 Genzyme Corporation Chemokine receptor binding compounds
AU2007225836A1 (en) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient

Also Published As

Publication number Publication date
BRPI0708731A2 (pt) 2011-06-07
US20090131403A1 (en) 2009-05-21
US8003642B2 (en) 2011-08-23
KR20090008217A (ko) 2009-01-21
MX2008011414A (es) 2008-09-22
EP1995246A4 (en) 2010-11-17
ZA200807767B (en) 2009-08-26
CN101443322A (zh) 2009-05-27
JPWO2007105637A1 (ja) 2009-07-30
CA2644368A1 (en) 2007-09-20
RU2008140144A (ru) 2010-04-20
AU2007225836A1 (en) 2007-09-20
WO2007105637A1 (ja) 2007-09-20
EP1995246A1 (en) 2008-11-26
MA30294B1 (fr) 2009-03-02
EA200870344A1 (ru) 2009-04-28

Similar Documents

Publication Publication Date Title
NO20083813L (no) Nitrogenholdig heterocyklisk derivat, og farmasoytisk middel omfattende derivatet som aktiv bestanddel
NO20071342L (no) Nitrogenholdig heterocyklisk derivat og medisin inneholdende det samme som en aktiv bestanddel.
NO20054244L (no) Nitrogeninneholdende heterocykliske derivater og legemidler inneholdende de samme som den aktive bestanddel
ME01515B (me) PIRIMIDINSKI DERIVATI ZA TRETMAN ASTME, HOBP, ALERGIJSKOG RINITISA, ALERGIJSKOG KONJUNKTIVITISA, ATOPIČNOG DERMATITISA, RAKA, HEPATITISA B, HEPATITISA C, HIV-a, HPV-a, BAKTERIJSKIH INFEKCIJA I DERMATOZE
NO20073926L (no) Pyrazolforbindelser som modulerer aktivitet av CDK-, GSK- og aurorakinaser
Kale et al. Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA gyrase B
NO20084645L (no) Cyklopropyl kondenserte indolobenzazepin HCV NS5B inhibitorer
NO20091599L (no) Kjemiske forbindelser
NO20083358L (no) Piperasinyl derivater som modulatorer for kjemokine reseptor aktivitet
NO20073849L (no) Indolderivater for behandling av virale infeksjoner
NO20073105L (no) Pyridazinonforbindelser
NO20084637L (no) Cyklopropyl-kondenserte indolobenzaepin HCV NS5B inhibitorer
NO20076450L (no) Heterosykliske forbindelser som nikotinsyrereseptoragonister for behandling av dyslipidemi
NO20074613L (no) Tricykliske nukleosidforbindelser for behandling av virale infeksjoner
NO20085176L (no) Fenyl substituerte heteroaryl-derivater og andvendelse som anti-tumor agenter
NO20090202L (no) Prolylhydroksylaseinhibitorer
NO20082934L (no) Antivirale nukleotider
WO2007103550A3 (en) Substituted aminothiazole derivatives with anti-hcv activity
EA201000201A1 (ru) Азотсодержащие бициклические химические вещества для лечения вирусных инфекций
NO20080879L (no) HCV-NS3-proteaseinhibitorer
MX2009010503A (es) Compuestos heterociclicos antiviricos.
NO20092053L (no) HCV NS3-proteaseinhibitorer
NO20092286L (no) Nitrogenhaldige heterosykliske forbindelser og anvendelse derav
NO20091683L (no) Kjemiske forbindelser
NO20081217L (no) Nye benzotiazolonderivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application